Scynexis is a New Jersey-based biotechnology company that researches, develops, and commercializes novel anti-infective therapies for the treatment of fungal infections... Read more
Scynexis is a New Jersey-based biotechnology company that researches, develops, and commercializes novel anti-infective therapies for the treatment of fungal infections... Read more
News
Apr 08, 2025
Benzinga
SCYNEXIS: SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
Mar 13, 2025
Owler
SCYNEXIS, Inc.: SCYNEXIS's employee count changed from 29 in Mar 2024 to 28 in Dec 2024
Mar 13, 2025
Seeking Alpha
SCYNEXIS: SCYNEXIS GAAP EPS of -$0.44 misses by $0.98, revenue of $3.75M misses by $63.25M
Mar 12, 2025
StreetInsider
Press Release: SCYNEXIS : SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
Dec 19, 2024
Nasdaq
SCYNEXIS: SCYNEXIS Begins Phase 1 Trial Of SCY-247 For Severe Invasive Fungal Infections
Nov 07, 2024
Owler
SCYNEXIS, Inc.: SCYNEXIS's revenue changed from $9.67M in Jun 2024 to $8.56M in Sep 2024
Nov 06, 2024
Yahoo
SCYNEXIS: Scynexis: Q3 Earnings Snapshot
Oct 10, 2024
centralcharts
Press Release: SCYNEXIS : SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
Oct 03, 2024
Benzinga
SCYNEXIS: SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
Aug 27, 2024
GlobeNewswire
Press Release: SCYNEXIS : SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
SCYNEXIS Competitors
1
2
3
4
5
6
7
8
9
10